Research Report For Adverum Biotechnologies, Inc. (ADVM)


Adverum Biotechnologies, Inc. (ADVM) will report its next earnings on Aug 08 AMC. The company reported the earnings of $-0.3/Share in the last quarter where the estimated EPS by analysts was $-0.29/share. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -3.4%.

Many analysts are providing their Estimated Earnings analysis for Adverum Biotechnologies, Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.31/share. These analysts have also projected a Low Estimate of $-0.31/share and a High Estimate of $-0.3/share.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Adverum Biotechnologies, Inc. might touch $12 high while the Average Price Target and Low price Target is $11 and $10 respectively.

The Relative Volume of the company is 2.53 and Average Volume (3 months) is 707.83 million.

The company shows its Return on Assets (ROA) value of -26.4%. The Return on Equity (ROE) value stands at -28.5%. While it’s Return on Investment (ROI) value is -26.5%.

While looking at the Stock’s Performance, Adverum Biotechnologies, Inc. currently shows a Weekly Performance of -2.7%, where Monthly Performance is -6.9%, Quarterly performance is -16.28%, 6 Months performance is 27.06% and yearly performance percentage is 111.76%. Year to Date performance value (YTD perf) value is 54.29%. The Stock currently has a Weekly Volatility of 8.21% and Monthly Volatility of 7.29%.